SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Ceragon Networks Ltd. – ‘20-F’ for 12/31/20 – ‘EX-4.12’

On:  Monday, 3/8/21, at 11:25am ET   ·   For:  12/31/20   ·   Accession #:  1178913-21-952   ·   File #:  0-30862

Previous ‘20-F’:  ‘20-F’ on 3/31/20 for 12/31/19   ·   Next:  ‘20-F’ on 5/2/22 for 12/31/21   ·   Latest:  ‘20-F’ on 3/21/24 for 12/31/23   ·   10 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/08/21  Ceragon Networks Ltd.             20-F       12/31/20  109:11M                                    Z-K Global Ltd./FA

Annual or Annual-Transition Report by a Foreign Non-Canadian Issuer   —   Form 20-F   —   SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual or Annual-Transition Report by a Foreign     HTML   1.53M 
                Non-Canadian Issuer                                              
 2: EX-2.1      Plan of Acquisition, Reorganization, Arrangement,   HTML     55K 
                Liquidation or Succession -- exhibit_2-1                         
 3: EX-4.12     Instrument Defining the Rights of Security Holders  HTML     83K 
                -- exhibit_4-12                                                  
 4: EX-4.13     Instrument Defining the Rights of Security Holders  HTML    463K 
                -- exhibit_4-13                                                  
 5: EX-4.14     Instrument Defining the Rights of Security Holders  HTML     43K 
                -- exhibit_4-14                                                  
 6: EX-8.1      Opinion of Counsel re: Tax Matters -- exhibit_8-1   HTML     30K 
 9: EX-13.1     Annual or Quarterly Report to Security Holders --   HTML     31K 
                exhibit_13-1                                                     
 7: EX-12.1     Statement re: the Computation of Ratios --          HTML     36K 
                exhibit_12-1                                                     
 8: EX-12.2     Statement re: the Computation of Ratios --          HTML     36K 
                exhibit_12-2                                                     
10: EX-15.1     Letter re: Unaudited Interim Financial Info --      HTML     30K 
                exhibit_15-1                                                     
11: EX-15.2     Letter re: Unaudited Interim Financial Info --      HTML     30K 
                exhibit_15-2                                                     
18: R1          Document And Entity Information                     HTML     94K 
19: R2          Consolidated Balance Sheets                         HTML    129K 
20: R3          Consolidated Balance Sheets (Parenthetical)         HTML     44K 
21: R4          Consolidated Statements of Operations               HTML     98K 
22: R5          Consolidated Statements of Comprehensive Income     HTML     60K 
                (Loss)                                                           
23: R6          Consolidated Statements of Changes in               HTML     76K 
                Shareholders' Equity                                             
24: R7          Consolidated Statements of Cash Flows               HTML    106K 
25: R8          General                                             HTML     36K 
26: R9          Significant Accounting Policies                     HTML    117K 
27: R10         Other Accounts Receivable and Prepaid Expenses      HTML     47K 
28: R11         Inventories                                         HTML     43K 
29: R12         Property and Equipment, Net                         HTML     56K 
30: R13         Intangible Assets, Net                              HTML     56K 
31: R14         Other Accounts Payable and Accrued Expenses         HTML     49K 
32: R15         Credit Lines                                        HTML     34K 
33: R16         Derivative Instruments                              HTML     87K 
34: R17         Credit Losses                                       HTML     43K 
35: R18         Pension Liabilities, Net                            HTML     89K 
36: R19         Commitments and Contingent Liabilities              HTML     51K 
37: R20         Leases                                              HTML     62K 
38: R21         Shareholders' Equity                                HTML    162K 
39: R22         Taxes on Income                                     HTML    153K 
40: R23         Revenues                                            HTML     53K 
41: R24         Segments, Customers and Geographic Information      HTML     71K 
42: R25         Selected Statements of Operations Data              HTML     93K 
43: R26         Related Party Balances and Transactions             HTML     72K 
44: R27         Significant Accounting Policies (Policies)          HTML    173K 
45: R28         Significant Accounting Policies (Tables)            HTML     70K 
46: R29         Other Accounts Receivable and Prepaid Expenses      HTML     47K 
                (Tables)                                                         
47: R30         Inventories (Tables)                                HTML     44K 
48: R31         Property and Equipment, Net (Tables)                HTML     55K 
49: R32         Intangible Assets, Net (Tables)                     HTML     55K 
50: R33         Other Accounts Payable and Accrued Expenses         HTML     49K 
                (Tables)                                                         
51: R34         Derivative Instruments (Tables)                     HTML     89K 
52: R35         Credit Losses (Tables)                              HTML     39K 
53: R36         Pension Liabilities, Net (Tables)                   HTML     85K 
54: R37         Leases (Tables)                                     HTML     62K 
55: R38         Shareholders' Equity (Tables)                       HTML    162K 
56: R39         Taxes on Income (Tables)                            HTML    140K 
57: R40         Revenues (Tables)                                   HTML     53K 
58: R41         Segments, Customers and Geographic Information      HTML     64K 
                (Tables)                                                         
59: R42         Selected Statements of Operations Data (Tables)     HTML     95K 
60: R43         Related Party Balances and Transactions (Tables)    HTML     67K 
61: R44         General (Narrative) (Details)                       HTML     50K 
62: R45         Significant Accounting Policies (Narrative)         HTML     56K 
                (Details)                                                        
63: R46         Significant Accounting Policies (Schedule Of        HTML     38K 
                Annual Depreciation Rates) (Details)                             
64: R47         Significant Accounting Policies (Schedule Of Stock  HTML     46K 
                Option Granted Assumptions) (Details)                            
65: R48         Significant Accounting Policies (Schedule of        HTML     52K 
                Accumulated Other Comprehensive Income, Net)                     
                (Details)                                                        
66: R49         Other Accounts Receivable and Prepaid Expenses      HTML     44K 
                (Details)                                                        
67: R50         Inventories (Details)                               HTML     42K 
68: R51         Property and Equipment, Net (Details)               HTML     51K 
69: R52         Intangible Assets, Net (Schedule Of Intangible      HTML     54K 
                Assets) (Details)                                                
70: R53         Other Accounts Payable and Accrued Expenses         HTML     48K 
                (Details)                                                        
71: R54         Credit Lines (Narrative) (Details)                  HTML     55K 
72: R55         Derivative Instruments (Schedule of Fair Value of   HTML     47K 
                Derivative Contracts) (Details)                                  
73: R56         Derivative Instruments (Schedule of Derivative      HTML     34K 
                Contracts on Consolidated Statements of                          
                Operations) (Details)                                            
74: R57         Derivative Instruments (Schedule Of Assets And      HTML     34K 
                Liabilities Measured At Fair Value On Recurring                  
                Basis) (Details)                                                 
75: R58         Credit Losses (Schedule of Allowance for Credit     HTML     40K 
                Losses) (Details)                                                
76: R59         Pension Liabilities, Net (Narrative) (Details)      HTML     35K 
77: R60         Pension Liabilities, Net (Schedule Of Changes In    HTML     45K 
                Projected Benefit Obligations) (Details)                         
78: R61         Pension Liabilities, Net (Schedule Of Assumptions   HTML     34K 
                Used) (Details)                                                  
79: R62         Pension Liabilities, Net (Summary Of Components Of  HTML     40K 
                Net Periodic Benefit Cost) (Details)                             
80: R63         Pension Liabilities, Net (Schedule Of Expected      HTML     42K 
                Benefit Payments) (Details)                                      
81: R64         Commitments and Contingent Liabilities (Narrative)  HTML     50K 
                (Details)                                                        
82: R65         Leases (Narrative) (Details)                        HTML     38K 
83: R66         Leases (Schedule of Components of Lease Expense     HTML     42K 
                and Supplemental Cash Flow Information) (Details)                
84: R67         Leases (Schedule of Maturities of Lease             HTML     47K 
                Liabilities) (Details)                                           
85: R68         Shareholders' Equity (Narrative) (Details)          HTML     57K 
86: R69         Shareholders' Equity (Summary Of Stock Options      HTML     81K 
                Granted) (Details)                                               
87: R70         Shareholders' Equity (Schedule of RSUs Granted)     HTML     51K 
                (Details)                                                        
88: R71         Shareholders' Equity (Summary Of Stock Options And  HTML     84K 
                RSUs Granted Separated Into Ranges Of Exercise                   
                Price) (Details)                                                 
89: R72         Shareholders' Equity (Schedule Of Equity-Based      HTML     39K 
                Compensation Expense) (Details)                                  
90: R73         Taxes on Income (Narrative) (Details)               HTML     76K 
91: R74         Taxes on Income (Schedule Of Income Tax Expense     HTML     45K 
                (Benefit)) (Details)                                             
92: R75         Taxes on Income (Schedule Of Deferred Income        HTML     41K 
                Taxes) (Details)                                                 
93: R76         Taxes on Income (Schedule Of Income (Loss) Before   HTML     39K 
                Taxes) (Details)                                                 
94: R77         Taxes on Income (Schedule Of Income Tax             HTML     58K 
                Reconciliation) (Details)                                        
95: R78         Taxes on Income (Schedule Of Changes In             HTML     39K 
                Unrecognized Tax Benefits) (Details)                             
96: R79         Revenues (Schedule of Significant Changes in        HTML     40K 
                Deferred Revenue) (Details)                                      
97: R80         Revenues (Schedule of Remaining Performance         HTML     39K 
                Obligations) (Details)                                           
98: R81         Segments, Customers and Geographic Information      HTML     58K 
                (Schedule Of Revenues From Sales To Unaffiliated                 
                Customers) (Details)                                             
99: R82         Segments, Customers and Geographic Information      HTML     40K 
                (Schedule Of Major Customer Data As Percentage Of                
                Total Revenues) (Details)                                        
100: R83         Selected Statements of Operations Data (Narrative)  HTML     32K  
                (Details)                                                        
101: R84         Selected Statements of Operations Data (Schedule    HTML     52K  
                Of Financial Expenses and Others, Net) (Details)                 
102: R85         Selected Statements of Operations Data (Schedule    HTML     48K  
                Of Net income per share) (Details)                               
103: R86         Related Party Balances and Transactions             HTML     57K  
                (Narrative) (Details)                                            
104: R87         Related Party Balances and Transactions (Schedule   HTML     46K  
                Of Transaction With Related Parties) (Details)                   
105: R88         Related Party Balances and Transactions (Schedule   HTML     36K  
                Of Balances With Related Parties) (Details)                      
107: XML         IDEA XML File -- Filing Summary                      XML    200K  
17: XML         XBRL Instance -- crnt20f1220_htm                     XML   2.53M 
106: EXCEL       IDEA Workbook of Financial Reports                  XLSX    129K  
13: EX-101.CAL  XBRL Calculations -- crnt-20201231_cal               XML    205K 
14: EX-101.DEF  XBRL Definitions -- crnt-20201231_def                XML    573K 
15: EX-101.LAB  XBRL Labels -- crnt-20201231_lab                     XML   1.25M 
16: EX-101.PRE  XBRL Presentations -- crnt-20201231_pre              XML   1.08M 
12: EX-101.SCH  XBRL Schema -- crnt-20201231                         XSD    227K 
108: JSON        XBRL Instance as JSON Data -- MetaLinks              482±   670K  
109: ZIP         XBRL Zipped Folder -- 0001178913-21-000952-xbrl      Zip    450K  


‘EX-4.12’   —   Instrument Defining the Rights of Security Holders — exhibit_4-12


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 

Exhibit 4.12

This document is to be signed by the parties
 
Amendment No. 10 to the Financing Agreement of March 14, 2013
 
Made and signed in Tel Aviv on June ___ 2020
 
by and between:
 
The parties enumerated in Appendix 1 to the Financing Agreement
 
in their capacity as Financiers (hereinafter: the “Financiers”).         
of the first part;

and:
 
Bank Hapoalim Ltd.
 
in its capacity as the Credit Manager and Collateral Trustee          
 
(Hereinafter: “Bank Hapoalim”)         
 of the second part;

and:
 
Ceragon Networks Ltd.
 
Company No. 51-235244-4
 
of 24 Raoul Wallenberg Street, Tel Aviv 6971920
 
(The “Borrower”)         
 of the third part;

(Each of the Financiers, the Credit Manager, the Collateral Trustee and the Borrower: “Party,” and, jointly, the “Parties”).
 
Whereas
on March 14, 2013, the Borrower entered into a financing agreement with the Financiers, its appendices and attachments included, as amended from time to time (the “Financing Agreement)”, in and pursuant to which, inter alia, the Credit was provided to the Borrower; and
 
Whereas
the Borrower contacted the Financiers and requested various changes in the Financing Agreement, as stated in this Amendment below; and
 
Whereas
based on the veracity of the declarations and representations of the Borrower in the Financing Agreement and this Amendment, as stated below, and the performance of all of its obligations as stated in the Financing Agreement as amended by this Amendment, the Financiers granted the Borrower’s request, and all subject to and in accordance with the terms and provisions of the Financing Agreement and this Amendment.
 

Now, therefore, it is declared, stipulated and agreed between the parties as follows:
 
1.
General
 

1.1
The preamble to this Amendment constitutes an integral part hereof. All of the terms that are mentioned in this Amendment above and below will have the meanings ascribed to them in the Financing Agreement, unless expressly stated otherwise.
 

1.2
For the avoidance of doubt, it is hereby agreed that this Amendment constitutes part of the Credit Documents, as defined in Section 2 of the Financing Agreement.
 

1.3
In addition to any declaration, representation or undertaking of the Borrower in the Credit Documents (as this term is defined in the Financing Agreement) or in any other agreement or document that was provided or will be provided to the Financiers in connection with the Credit or the Collateral, without derogating from any of the above (except as required by this Amendment), the Borrower declares, certifies and undertakes toward the Financiers and Officers as follows:
 

1.3.1
That the Borrower complied and continues to comply with all of the provisions of the Financing Agreement, and to the letter.
 

1.3.2
That all of the Borrower’s representations that are included in the Financing Agreement (excluding those that are stated in Sections 15.1.2, 15.1.3(a), 15.1.5, 15.1.6, 15.1.10, 15.1.11 and 15.1.16) remain unchanged and they are correct and complete as of the date of signing this Amendment.
 

1.3.3
That: (a) the Borrower has obtained all of the decisions, agreements, authorizations, permits and certificates that are required under its constitutional documents, as required by law and in accordance with the instructions of any authority, in connection with making this Amendment or in connection with the Financing Agreement and its appendices; (b) there is no need to make decisions or provide agreements or for any other certificates; (c) all of the requisite steps and measures have been taken in order to lawfully certify its entering into this Amendment; (d) all of the obligations of the Borrower under, in the framework of or in connection with this Amendment or the Financing Agreement or the other Credit Documents are legal, in force, valid, binding and enforceable against it, according to their terms and conditions;
 
2.
Postponement of the Final Repayment Date
 

2.1
As of the date of signing this Amendment, Section 2 of the Financing Agreement will be amended such that the definition of “Final Repayment Date” in it is removed, and replaced by the following:
 
“Final Repayment Date” June 30, 2021.
 

3.
Increased loan amounts and decreased guarantee amounts
 

3.1
Without derogating from the provisions of Sections 18.8 and 18.9 of the Financing Agreement, as of the date of signing this Amendment:
 

(a)
the loan amount that was allocated by each of the Financiers will be amended such that the total amount of loans that will be allocated by all of the Financiers together will increase by USD 10 (ten) million (the “Addition”), as follows: (a) the share of HSBC with respect to the loans will remain unchanged; (B) the share of the other Financiers with respect to the loans (the “Other Financiers”) will increase by USD 10 (ten) million. The share of each of the Financiers with respect to the loans will be as stated in Appendix 1 to the Financing Agreement.
 

(b)
The amount of bank guarantees allocated by each of the Financiers together will decrease by USD 15 (fifteen) million (hereinafter: the “Reduction”), as follows: (a) the share of HSBC with respect to the bank guarantees will remain unchanged; (b) the share of the Other Financiers with respect to the bank guarantees (the “Other Financiers”) will decrease by USD 15 (fifteen) million. The share of each of the Financiers with respect to the bank guarantees will be as stated in Appendix 1 to the Financing Agreement.
 

3.2
As of the date of signing this Amendment, Appendix 1 to the Financing Agreement will be replaced by Appendix 1 that is attached to this Amendment, in accordance with the amendments in Section 3.1 above.
 

3.3
As of the date of signing this Amendment, Section 16.28.5 of the Financing Agreement will be amended such that Appendix 16.28.5 to the Financing Agreement is replaced by Appendix 16.28.5 that is attached to this Amendment.
 
4.
Amendment of the terms of the Insurance Arrangement
 

4.1
As of the date of signing this Amendment, Section 15.1.17 of the Financing Agreement will be amended such that, in the 13th (thirteenth) line, the words “20 (twenty)” will be removed and replaced by the words “50 (fifty).”
 
5.
Amendment of the Financing Agreement
 

5.1
As of the date of signing this Amendment, Section 1.15 of the Financing Agreement will be amended such that the existing section is removed in its entirety, and replaced by the following:
 
“1.15. The terms “Liquidation”, “Insolvency,” or “Suspension of Proceedings” will interpreted to include: (a) the appointment of a liquidator, special administrator, receiver, trustee or any similar officer and the appointment of any other person by any competent authority (whether in Israel or overseas), with respect to all or part of the property of the Borrower and/or significant subsidiary, or, if an motion is filed for such an appointment, be it temporary or permanent; (b) the filing of a motion for liquidation or a motion for receivership order or a motion for commencement of proceedings or a motion to recognize a foreign proceeding that pertains to insolvency or any other motion of a similar nature; (c) the passing of a resolution to liquidate or the granting of a liquidation order or a receivership order or a commencement of proceedings order (be its content as it may); (d) a motion for or the issuance of an economic rehabilitation order; or (e) a proposal or the certification of an arrangement or a proposed settlement between the Borrower and/or a significant subsidiary and its creditors or shareholders (in whole or in part), or the settlement of the Borrower’s debts and/or those of a significant subsidiary with respect to any of the creditors or shareholders; and (f) all proceedings that are analogous or similar to any of the above in Israel or overseas; any reference in this agreement to a “motion,” “proceeding,” “order,” “appointment” and so on will also include corresponding motions, proceedings, orders or appointments under the relevant foreign law.”
 


5.2
As of the date of signing this Amendment, the Financing Agreement will be amended such that, at the end of Sections 16.28.1 and 16.28.2 of the Financing Agreement, the following paragraph will be added:
 
“It is hereby clarified that a precondition for providing the Credit and its continued provision by the Financiers is the provision of the Financiers’ financial statements as stated in this section, and inter alia and as required pursuant to the instructions of the Bank of Israel or any other competent authority, or under applicable law.
 

5.3
As of the date of signing this Amendment, Section 17.3.5 of the Financing Agreement will be amended such that the Section is removed in its entirety and replaced by the following:
 
“17.3.5. If the Borrower and/or investee company passes a voluntary liquidation resolution, excluding in the framework of permitted structural changes, and/or if a motion to institute insolvency proceedings of any kind is filed against the Borrower and/or a significant subsidiary, including a motion for liquidation or a motion for bankruptcy, or a motion for commencement of proceedings order or a motion for  receivership order that is not canceled within 21 (twenty-one) days of its filing and/or if a liquidation order or a bankruptcy order or a commencement of proceedings order or a receivership order (be its content as it may) is issued against the Borrower and/or a significant subsidiary; and/or if, a temporary, permanent or other receiver is appointed, or a special administrator or trustee or receiver or any other receiver or administrator or officer is appointed for the Borrower and/or a significant subsidiary in connection with any of the cases that are set forth in this subsection above, by way of temporary or permanent appointment or any other appointment by any competent authority (whether in Israel or overseas); and/or if a motion for suspension of proceedings with respect to the Borrower and/or a significant subsidiary is filed (provided that, if this motion was filed without the Borrower’s consent and/or that of the Borrower’s shareholders and/or the significant subsidiary, as the case may be, is not canceled within 21 (twenty-one) days of its filing) and/or a suspension of proceeding order is issued as stated and/or a financial rehabilitation order and/or if resolutions are passed by the Borrower and/or a significant subsidiary to negotiate with any of the Borrower’s creditors and/or those of a significant subsidiary and/or if negotiations are held for the purpose of reaching an arrangement or a proposed settlement between the Borrower and/or a significant subsidiary and their creditors and/or shareholders (in whole or in part), or between them and any class thereof and/or the settlement of the Borrower’s debt and/or that of a significant subsidiary with respect to any of the creditors or shareholders and/or if an arrangement or proposed settlement is certified and/or if a motion is filed with the court for the appointment of an settlement expert with respect to the Borrower and/or a significant subsidiary, or if such an expert or another officer is appointed in connection with any of the cases that are set forth in this section above, by way of temporary or permanent appointment. This section will be interpreted as referring to all of the proceedings and orders that are stated in it and any to proceeding or order that is analogous or similar to them in Israel or overseas.”
 


5.4
As of the date of signing this Amendment, Section 17.3.6 of the Financing Agreement will be amended such that the Section is removed in its entirety and replaced by the following:
 
“17.3.6. If a motion to commence insolvency proceedings of any kind, including a motion for liquidation, motion for bankruptcy or motion for receivership order or motion for commencement of proceedings order is filed against an investee company (that is not a significant subsidiary) that is not canceled within 21 (twenty-one) business days of its filing and/or if a liquidation order or a bankruptcy order or a receivership order or a commencement of proceedings order (be its content as it may) is issued against an investee company (that is not a significant subsidiary) is issued that is not removed or canceled within 21 (twenty-one) business day; and/or a temporary, permanent or other liquidator or special administrator or trustee or receiver or any other receiver and administrator or other officer is appointed for an investee company (that is not a significant subsidiary), in connection with any of the cases that are enumerated in this subsection above, by way of temporary or permanent appointment, as well as any other appointment by any competent authority (whether in Israel or overseas), and the aforementioned appointment is not canceled within 21 (twenty-one) business days; if a motion to suspend proceedings is filed against an investee company (that is not a significant subsidiary); and/or if a motion to suspend proceeding as stated and/or an economic rehabilitation order is issued, provided that, if the motion to suspend proceedings was filed without the consent of the Borrower and/or investee company, as the case may be, it was not canceled within 21 (twenty-one) business days of its filing, and all if any of the aforementioned motions or orders were granted were issued with respect to debts that cumulatively exceed USD 5 (five) million, with respect to all of the investee companies against which such a motion was filed in that calendar year,; if resolutions are passed by an investee company (that is not a significant subsidiary) to negotiate with any of its creditors and/or if negotiations are held for the purpose of reaching a settlement or proposed settlement between an investee company (that is not a significant subsidiary) and its creditors (in whole or in part) or between it and any class thereof and/or if a settlement or proposed settlement is certified as stated and/or if a motion is filed with the court for the appointment of a settlement expert with respect to an investee company (that is not a significant subsidiary), or if such an expert or another officer is appointed in connection with any of the cases that are set forth in this section above, by way of temporary or permanent appointment, and provided that the settlement or proposed settlement refer to debts that cumulatively exceed USD 5 (five) million, with respect to all of the investee companies against which such a motion was filed in that calendar year.”
 

5.5
As of the date of signing this Amendment, Section 23.6.2 of the Financing Agreement will be amended such that the section is removed in its entirely and replaced by the following sections:
 
“23.6.2. The settlement of all of the amounts payable to the Financiers in accordance with the provisions of the Credit Documents pursuant to penalty interest, pro rata among the Financiers, and in accordance with the applicable distribution ratio.
 
26.6.2a. The settlement of all of the amounts payable to the Financiers in accordance with the provisions of the Credit Documents pursuant to interest of any kind (excluding penalty interest, which will be settled in accordance with Section 23.6.2 above), pro rata among the Financiers, and in accordance with the applicable distribution ratio.
 

6.
Payments
 

6.1
the Borrower undertakes to pay (a) Bank Hapoalim in its capacity as the Credit Manager, and (b) each Financier through the Credit Manager, a special, one-time and agreed upon amount in connection with the amendment of the Financing Agreement, and all as stated in the Supplementary Letter, which will be signed by the Borrower together with this Amendment.
 

6.2
Any payment as stated above will be regarded as final and conclusive, and will not be returned to the Borrower for any reason.
 
7.
Miscellaneous
 

7.1
Unless otherwise expressly stated in this Amendment, the conditions and obligations set forth in this Amendment do not derogate from or change any other obligation of the Borrower with respect to the Financiers or the validity of any collateral that was provided in favor of the Collateral Trustee for the Financiers, under and pursuant to the Financing Agreement or the other Credit Documents or any other document or agreement that was provided or that will be provided to the Financiers or an officer in connection with the Credit, and they will remain in full binding force, including all of the provisions that pertain to the Financiers’ rights to the Credit’s immediate repayment, and all in accordance with and subject to the provisions and conditions of the Credit Documents.
 

7.2
This Amendment, unless expressly stated otherwise therein, is in addition to everything that is stated in the Financing Agreement and the Amendments, without derogating from or changing them, and, unless otherwise expressly stated in this Amendment, all of the rights of the Financiers and the Borrower under the Financing Agreement, the Amendments and applicable law are fully reserved.
 

7.3
A single copy or several separate copies of this Amendment (by any of the parties) can be signed by the parties, which will together constitute a single document.
 
[The signatures are found on the next page]
 


In witness whereof the parties have hereunto set their hands:
 
Signature and Stamp]

Ceragon Networks Ltd.

Bank Hapoalim Ltd.

(In its capacity as the Credit Manager and Collateral Trustee)
First International Bank of Israel

[As Financier]

 
HSBC Bank PLC

[As Financier]

 
Bank Leumi Ltd.

[As Financier]
 


 
Certification
 
I, the undersigned, Adv. [Stamp] Zvi Maayan, EVP, General Counsel, Ceragon Networks Ltd., serving as a legal advisor of Ceragon Networks Ltd. (the “Borrower”), hereby certify that this Amendment was lawfully signed by the Borrower through [Illegible], I.D. No. 55492603 and Ran Vered, I.D. No. 031682743, pursuant to a lawfully passed resolution of the Borrower, and in accordance with the Borrower’s current constitutional documents. I also hereby certify that this agreement was signed through those authorized to obligate the Borrower, whose signature in this agreement is binding on the Borrower for all intents and purposes.
 

Date
Stamp] Zvi Maayan, EVP, General Counsel,
Ceragon Networks Ltd.

Signature and seal of attorney
 


Appendix 1 (Appendix 1 to Amendment No. 10 to the Financing Agreement)
 
List of financiers and list of credit obligations and permissible risk amounts of each Financier
 
1.
All of the terms in this Appendix will have the meanings ascribed to them in the Financing Agreement.
 
2.
The list of Financiers is as stated in this Appendix
 
     
Loan Amount Allocated by the Financier
Bank Guarantee Amount Allocated by the Financier
Permissible Risk Amount
1.
Bank Hapoalim Ltd.
Name: Mr. Amnon Kirmayer
Address: Business Department, Business Division, Central Management, Bank Hapoalim Ltd., 23 Menachem Begin Road, Tel Aviv-Jaffa
Tel.: 03-5674817
Fax: 03-7136367
USD
25,000,000
(twenty-five)
USD
41,000,000
(forty-one million)
USD
5,427,586
(five million, four hundred and twenty-seven, five hundred and eighty-six)
2.
Bank Leumi Ltd.
Name: Mr. Danny Shapira
Address: High-tech Department, Business Division, Bank Leumi, 34 Yehuda HaLevi Street, Tel Aviv-Jaffa 65136
Tel.: 076-885-9184
Fax: 077-8959184
USD
8,200,000
(eight million and two hundred thousand)
USD 
16,000,000
(sixteen million)
USD
1,000,000
(one million)
3.
First International Bank of Israel
Name: Ms. Naama Magid
Tel.: 03-5196239
Fax: 03-5196944
Name: Mr. Hezi Cupryk
Tel.: 03-619599;
Fax: 03-5196944
Address: Energy, Chemistry and Technology Sector of the Business Division, First International Bank of Israel Ltd., 42 Rothschild Street, Tel Aviv-Jaffa.
USD
8,000,000
(eight million)
USD
9,000,000
(nine million)
USD
3,982,759
(three million, nine hundred and eighty-two thousand, seven hundred and fifty-nine)
4.
HSBC Bank PLC (Tel Aviv Branch)
Name: Mr. Guy Birger
Address: 2 Jabotinsky Street, Ramat Gan, Amot Atrium Building, 30th Floor, 5250501
Tel.: 03-7101244
Fax: 03-7101144
USD 
8,800,000
(eight million and eight hundred thousand)
USD
4,000,000
(four million)
USD
400,000
(four hundred thousand)
Total
USD
50,000,000
(fifty million)
USD
70,000,000
(seventy million)
USD
10,810,345
(ten million, eight hundred and ten thousand, three hundred and fourty-five)


 
This document is to be signed by the parties
 
Report on usage of loan and bank guarantee amounts with respect to each Financier
 
1.
All of the terms in this Appendix will have the meanings ascribed to them in the Financing Agreement.
 
2.
The used amounts set forth in this appendix – Appendix 16.28.5 – below are as of _________ (with respect to calendar quarter No. ____ of the year ____).
 
 
Name of Financier
Loan Amount Allocated by the Financier
Loan Amount Used by the Borrower out of the Total Loan Amount Allocated by the Financier1
Bank Guarantee Amount Allocated by the Financier
Amount Used by the Borrower out of the Total Bank Guarantee Amount Allocated by the Financier2
1.
Bank Hapoalim Ltd.
USD
25,000,000
(twenty-five)
USD
_____________
(_____________)
USD
41,000,000
(forty-one million)
USD
_____________
(_____________)
2.
Bank Leumi Ltd.
USD
8,200,000
(eight million and two hundred thousand)
USD
_____________
(_____________)
USD 
16,000,000
(sixteen million)
USD
_____________
(_____________)
3.
First International Bank of Israel
USD
8,000,000
(eight million)
USD
_____________
(_____________)
USD
9,000,000
(nine million)
USD
_____________
(_____________)
4.
HSBC Bank PLC (Tel Aviv Branch)
USD 
8,800,000
(eight million and eight hundred thousand)
USD
_____________
(_____________)
USD
4,000,000
(four million)
USD
_____________
(_____________)
Total
USD
50,000,000
(fifty million)
USD
_____________
(_____________)
USD
70,000,000
(seventy million)
USD
_____________
(_____________)

 

1 The used loan amount also includes credit card amounts that were provided by a Financier (whether or not the credit card amounts were used, in whole or in part).
2 The aforementioned amount includes the unpaid principal of the long-term loan.



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘20-F’ Filing    Date    Other Filings
6/30/216-K
Filed on:3/8/21
For Period end:12/31/20SD
6/25/20
3/14/136-K,  SC 13G/A
 List all Filings 


3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/21/24  Ceragon Networks Ltd.             20-F       12/31/23  112:13M                                    Z-K Global Ltd./FA
 5/01/23  Ceragon Networks Ltd.             20-F       12/31/22  104:10M                                    Z-K Global Ltd./FA
 5/02/22  Ceragon Networks Ltd.             20-F       12/31/21  104:10M                                    Z-K Global Ltd./FA


7 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/31/20  Ceragon Networks Ltd.             20-F       12/31/19  105:9.9M                                   Z-K Global Ltd./FA
 3/27/18  Ceragon Networks Ltd.             20-F       12/31/17   98:9.2M                                   Z-K Global Ltd./FA
 4/07/17  Ceragon Networks Ltd.             20-F       12/31/16  100:9M                                     Z-K Global Ltd./FA
 3/23/16  Ceragon Networks Ltd.             20-F       12/31/15  108:9.4M                                   Z-K Global Ltd./FA
 4/02/15  Ceragon Networks Ltd.             20-F       12/31/14  116:18M                                    Z-K Global Ltd./FA
11/19/13  Ceragon Networks Ltd.             6-K        11/19/13   53:3.6M                                   Z-K Global Ltd./FA
 4/03/13  Ceragon Networks Ltd.             20-F       12/31/12  115:15M                                    Z-K Global Ltd./FA
Top
Filing Submission 0001178913-21-000952   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., May 12, 2:50:04.2am ET